TheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
TheraP: a randomized phase 2 trial of 177
Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)
Authors
Keywords
-
Journal
BJU INTERNATIONAL
Volume 124, Issue -, Pages 5-13
Publisher
Wiley
Online
2019-10-22
DOI
10.1111/bju.14876
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prostate-specific Membrane Antigen Across the Spectrum of Prostate Cancer: Detection, Surgery, and Theranostics
- (2019) Declan G. Murphy et al. EUROPEAN UROLOGY
- A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol
- (2018) Michael S. Hofman et al. BJU INTERNATIONAL
- Accuracy of Dose Calibrators for68Ga PET Imaging: Unexpected Findings in a Multicenter Clinical Pretrial Assessment
- (2018) Dale L. Bailey et al. JOURNAL OF NUCLEAR MEDICINE
- [ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
- (2018) Michael S Hofman et al. LANCET ONCOLOGY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Results of a prospective phase 2 pilot trial of Lu177 PSMA 617 therapy for metastatic castrate resistant prostate cancer including Imaging predictors of treatment response and patterns of progression.
- (2018) Louise Emmett et al. Clinical Genitourinary Cancer
- The trajectory of patients who die from metastatic prostate cancer: a population-based study
- (2018) Anna Collins et al. BJU INTERNATIONAL
- Rapid modulation of PSMA expression by Androgen deprivation: Serial 68Ga PSMA-11 PET in men with hormone sensitive and castrate resistant prostate cancer commencing androgen blockade.
- (2018) Louise M Emmett et al. JOURNAL OF NUCLEAR MEDICINE
- Dosimetry of Lu-177 PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pre-therapeutic imaging and “whole body” tumor dosimetry with treatment outcomes
- (2018) John A Violet et al. JOURNAL OF NUCLEAR MEDICINE
- Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer
- (2018) Katharina Lückerath et al. EJNMMI Research
- Radiation Dosimetry for 177 Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions
- (2016) Shozo Okamoto et al. JOURNAL OF NUCLEAR MEDICINE
- Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis
- (2016) K. Rahbar et al. JOURNAL OF NUCLEAR MEDICINE
- PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617
- (2016) C. Kratochwil et al. JOURNAL OF NUCLEAR MEDICINE
- 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy
- (2016) R. P. Baum et al. JOURNAL OF NUCLEAR MEDICINE
- Radioligand therapy with 177 Lu-PSMA-617 of metastatic prostate cancer has already been arrived in clinical use
- (2016) Hojjat Ahmadzadehfar et al. NUCLEAR MEDICINE AND BIOLOGY
- Radionuklidtherapie des Prostatakarzinoms mittels PSMA-Lutetium
- (2016) M. M. Heck et al. UROLOGE
- Radionuklidtherapie des Prostatakarzinoms mittels PSMA-Lutetium
- (2016) M. M. Heck et al. UROLOGE
- Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer
- (2015) Andreas Delker et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
- (2015) Charles J Ryan et al. LANCET ONCOLOGY
- Addition of PSMA ADC to enzalutamide therapy significantly improves survival in in vivo model of castration resistant prostate cancer
- (2015) Vincent A. DiPippo et al. PROSTATE
- WIDEN: A tool for medical image management in multicenter clinical trials
- (2014) Stéphane Chauvie et al. Clinical Trials
- Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy
- (2014) Christian M. Zechmann et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2010) A. Horwich et al. ANNALS OF ONCOLOGY
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now